Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
Dumb bears will keep shorting here
-
Unless they shorted in the PRE MARKET when it was $210
-
Come on, this fight of the $186 should be done already. The bears are just fighting it for sentimental value, because at that point none of them are in the green anymore.
-
If it wasn’t for the stupid Bank of America so called analysts, $MRNA would be already hitting the $300
-
Bears are fighting hard to keep it below the $186. As soon they give up, we will be heading to the $200 fast. So fast those hedge funds bears won’t even have time to cry. They will just faint.
-
-
The shorts that got in with the horrible guidance from Bank of America are loosing. They should go after Bank of America for misguiding them. Lol.
Just a reminder to old and new shorts. You better have a lot more money, otherwise you will end up like some hedge funds from a week ago crying on national television.
$MRNA is actually making billions, it will report an EPS jump of over 5000% year over year. So the price of the stock has plenty to go up due to their new EPS that will be reported in 2 weeks. -
We will be at $250-$260 before earnings, and after earnings report, we will jump to the $300s. A lot of Investors are waiting for the first report to make sure $MRNA is a real solid investment.
New investors will make good money, but early investors let’s just say, are going to be extra happy. -
As soon the $185.99 is done. The $200 is next.
-
-
Some people posting here that they have found a stock way better than $MRNA.
That $OCGN crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks. Yes, go look at their charts, open the 5 year.
Totally opposite of $MRNA. Plus moderna is actually selling a vaccine and making billions. Yes, billions are already in the bank. We are not waiting for trials or hoping to have high efficacy or even looking for buyers. We have a solid vaccine and it is sold out. We are just waiting on FDA to give the green light to be able to add %50 more doses per vial. By the way I doubt they will say no.
$OCGN is essentially the twin stock of game stop. But with a huge difference. Game stop was shorted 112%. This $OCGN crap is only shorted 9%. Not even there they have a good setup for a short squeeze. It is a very bad choice. As you can also see how bad it was for the people that got into game stop after already jumped.
-
That $OCNG crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks. Yes, go look at their charts, open the 5 year.
Totally opposite of $MRNA. Plus moderna is actually selling a vaccine and making billions. Yes, billions are already in the bank. We are not waiting for trials or hoping to have high efficacy or even looking for buyers. We have a solid vaccine and it is sold out. We are just waiting on FDA to give the green light to be able to add %50 more doses per vial. By the way I doubt they will say no.
$OCNG is essentially the twin stock of game stop. But with a huge difference. Game stop was shorted 112%. This $OCNG crap is only shorted 9%. Not even there they have a good setup for a short squeeze. It is a very bad choice. As you can also see how bad it was for the people that got into game stop after already jumped.
-
That $OCNG crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks.
Totally opposite of $MRNA.
$OCNG is essentially the twin stock of Game stop. Now you know
-
By the way, when you get the vaccine. The only one protected is you. You can still get COVID-19 and spread it. With the vaccine you just act like a asymptomatic and have the 94-95% chances to be fine. With the other vaccines your chances are less and you might end up getting sick anyway.
-
-
That’s is because they want Moderna investors and traders to go to their stocks promising that they will sell more vaccines than Moderna.
The thing is if you get out of moderna before earnings. You will miss the biggest jump Moderna have done. So, just be smart or you can go and someone else will buy your share and make the money -
Bears are just playing with fire right now. And they are about to get burned.
The big news is coming out over the weekend. -
-
Is that the little pullback we needed to finally sprint to the $180?
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •